Skip to main content

Table 4 Proportion of patients achieving ≥ 0.5-point reductions in ACQ-5 score, by baseline characteristics

From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

  Mepolizumab   Placebo
ITT population
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n (%) 272/465 (58)   201/462 (44)
 Odds ratio (mepolizumab/placebo), 95% CI; p-value   1.91 (1.45, 2.52); p < 0.001  
Age at asthma onset: < 18 years
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 78/132 (59)   50/119 (42)
 Odds ratio (mepolizumab/placebo), 95% CI   1.84 (1.06, 3.20)  
Age at asthma onset: 18–< 40 years
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 93/172 (54)   69/171 (40)
 Odds ratio (mepolizumab/placebo), 95% CI   1.93 (1.20, 3.12)  
Age at asthma onset: ≥ 40 years
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 100/160 (63)   82/172 (48)
 Odds ratio (mepolizumab/placebo), 95% CI   2.27 (1.39, 3.70)  
Lung function: ≤ 60% predicted FEV1
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 149/243 (61)   95/238 (40)
 Odds ratio (mepolizumab/placebo), 95% CI   2.53 (1.73, 3.71)  
Lung function: > 60–80% predicted FEV1
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 101/176 (57)   86/177 (49)
 Odds ratio (mepolizumab/placebo), 95% CI   1.40 (0.87, 2.24)  
Lung function: ≥ 80% predicted FEV1
 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%) 22/46 (48)   20/47 (43)
 Odds ratio (mepolizumab/placebo), 95% CI   1.45 (0.47, 4.48)  
  1. ACQ Asthma Control Questionnaire, CI confidence interval, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat